Biohaven Ltd. (NYSE:BHVN) CEO Vlad Coric Purchases 121,951 Shares

Biohaven Ltd. (NYSE:BHVN) CEO Vlad Coric bought 121,951 shares of the business’s stock in a transaction dated Monday, April 22nd. The shares were bought at an average cost of $41.00 per share, for a total transaction of $4,999,991.00. Following the purchase, the chief executive officer now directly owns 1,788,417 shares in the company, valued at approximately $73,325,097. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Biohaven Stock Performance

BHVN stock opened at $38.32 on Tuesday. The business has a 50 day simple moving average of $51.63 and a two-hundred day simple moving average of $41.70. Biohaven Ltd. has a 1-year low of $12.35 and a 1-year high of $62.21.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). Equities analysts predict that Biohaven Ltd. will post -5.85 EPS for the current year.

Institutional Investors Weigh In On Biohaven

Large investors have recently bought and sold shares of the business. Point72 Asset Management L.P. lifted its position in Biohaven by 142.2% during the fourth quarter. Point72 Asset Management L.P. now owns 2,483,567 shares of the company’s stock valued at $106,297,000 after purchasing an additional 1,458,072 shares during the last quarter. Bellevue Group AG purchased a new stake in shares of Biohaven during the 4th quarter valued at about $46,010,000. Perceptive Advisors LLC raised its position in shares of Biohaven by 129.4% during the 4th quarter. Perceptive Advisors LLC now owns 1,725,047 shares of the company’s stock valued at $73,832,000 after buying an additional 973,227 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Biohaven by 33.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,134,323 shares of the company’s stock valued at $134,150,000 after acquiring an additional 791,181 shares during the last quarter. Finally, Redmile Group LLC purchased a new position in Biohaven in the third quarter worth about $13,497,000. Institutional investors own 88.78% of the company’s stock.

Analyst Ratings Changes

BHVN has been the topic of several recent research reports. TD Cowen upped their price target on Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a research note on Friday, March 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Thursday, April 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $61.00 target price on shares of Biohaven in a research note on Tuesday, April 9th. UBS Group started coverage on shares of Biohaven in a research note on Tuesday, February 6th. They issued a “buy” rating and a $59.00 price objective on the stock. Finally, JPMorgan Chase & Co. lifted their target price on Biohaven from $32.00 to $56.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Biohaven has a consensus rating of “Buy” and an average price target of $52.00.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.